表紙
市場調査レポート

Koronis Pharma, Inc. - 製品パイプライン分析

Koronis Pharma, Inc. - Product Pipeline Review - 2014

発行 Global Markets Direct 商品コード 310648
出版日 ページ情報 英文 24 Pages
即納可能
価格
本日の銀行送金レート: 1USD=107.50円で換算しております。
Back to Top
Koronis Pharma, Inc. - 製品パイプライン分析 Koronis Pharma, Inc. - Product Pipeline Review - 2014
出版日: 2014年08月14日 ページ情報: 英文 24 Pages
概要

Koronis Pharma, Inc. は、ウィする崩壊促進機序に基づいた抗ウィルス製剤を開発するバイオテクノロジー企業です。主にエイズ、C型肝炎などの治療薬の開発を行っています。

当レポートでは、Koronis Pharma, Inc.における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

Koronis Pharma, Inc.の基本情報

Koronis Pharma, Inc.の概要

  • 主要情報
  • 企業情報

Koronis Pharma, Inc.:R&D

  • 主な治療範囲

Koronis Pharma, Inc.:パイプラインレビュー

  • 開発段階別パイプライン製品
  • 単剤製品

Koronis Pharma, Inc.:パイプライン製品概況

  • 治験段階にあるパイプライン製品
    • 第II相にある製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階にある製品/併用療法モダリティ
    • 創薬中の製品/併用療法モダリティ

Koronis Pharma, Inc.:薬剤プロファイル

  • KP-1461
  • KP-1212
  • Small Molecule for Hepatitis C

Koronis Pharma, Inc.:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

Koronis Pharma, Inc.:最近のパイプライン動向

Koronis Pharma, Inc.:休止中のプロジェクト

Koronis Pharma, Inc.:本社と子会社の所在地

付録

図表

目次
Product Code: GMDHC06147CDB

Summary

Global Markets Direct's, 'Koronis Pharma, Inc. - Product Pipeline Review - 2014', provides an overview of the Koronis Pharma, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Koronis Pharma, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Koronis Pharma, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Koronis Pharma, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Koronis Pharma, Inc.'s pipeline products

Reasons to buy

  • Evaluate Koronis Pharma, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Koronis Pharma, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Koronis Pharma, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Koronis Pharma, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Koronis Pharma, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Koronis Pharma, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Koronis Pharma, Inc. Snapshot
    • Koronis Pharma, Inc. Overview
    • Key Information
    • Key Facts
  • Koronis Pharma, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Koronis Pharma, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Koronis Pharma, Inc. - Pipeline Products Glance
    • Koronis Pharma, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • Koronis Pharma, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Koronis Pharma, Inc. - Drug Profiles
    • KP-1461
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • KP-1212
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Hepatitis C
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Koronis Pharma, Inc. - Pipeline Analysis
    • Koronis Pharma, Inc. - Pipeline Products by Target
    • Koronis Pharma, Inc. - Pipeline Products by Route of Administration
    • Koronis Pharma, Inc. - Pipeline Products by Molecule Type
    • Koronis Pharma, Inc. - Pipeline Products by Mechanism of Action
  • Koronis Pharma, Inc. - Recent Pipeline Updates
  • Koronis Pharma, Inc. - Dormant Projects
  • Koronis Pharma, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Koronis Pharma, Inc., Key Information
  • Koronis Pharma, Inc., Key Facts
  • Koronis Pharma, Inc. - Pipeline by Indication, 2014
  • Koronis Pharma, Inc. - Pipeline by Stage of Development, 2014
  • Koronis Pharma, Inc. - Monotherapy Products in Pipeline, 2014
  • Koronis Pharma, Inc. - Phase II, 2014
  • Koronis Pharma, Inc. - Preclinical, 2014
  • Koronis Pharma, Inc. - Discovery, 2014
  • Koronis Pharma, Inc. - Pipeline by Target, 2014
  • Koronis Pharma, Inc. - Pipeline by Route of Administration, 2014
  • Koronis Pharma, Inc. - Pipeline by Molecule Type, 2014
  • Koronis Pharma, Inc. - Pipeline Products by Mechanism of Action, 2014
  • Koronis Pharma, Inc. - Recent Pipeline Updates, 2014
  • Koronis Pharma, Inc. - Dormant Developmental Projects,2014

List of Figures

  • Koronis Pharma, Inc. - Pipeline by Top 10 Indication, 2014
  • Koronis Pharma, Inc. - Pipeline by Stage of Development, 2014
  • Koronis Pharma, Inc. - Monotherapy Products in Pipeline, 2014
  • Koronis Pharma, Inc. - Pipeline by Top 10 Target, 2014
  • Koronis Pharma, Inc. - Pipeline by Top 10 Route of Administration, 2014
  • Koronis Pharma, Inc. - Pipeline by Top 10 Molecule Type, 2014
  • Koronis Pharma, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2014
Back to Top